Robert P. Perrillo

Robert P. Perrillo's AcademicInfluence.com Rankings

Robert P. Perrillo

Philosophy

#9066

World Rank

#12566

Historical Rank

Logic

#6063

World Rank

#7544

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert P. Perrillo's Degrees

Doctorate Medicine Harvard University

Why Is Robert P. Perrillo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert P. Perrillo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Lamivudine as initial treatment for chronic hepatitis B in the United States. (1999) (1366)
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa (1989) (1328)
National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C (1997) (1042)
A preliminary trial of lamivudine for chronic hepatitis B infection. (1995) (838)
A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B (1990) (757)
Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis (1992) (646)
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. (2015) (598)
Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants (2000) (428)
Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. (2001) (427)
A multicenter United States—Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B (2001) (418)
Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. (1989) (415)
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. (2004) (404)
Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. (1993) (367)
Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial (2004) (347)
Long‐term mortality and morbidity of transfusion‐associated non‐A, non‐B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study (2001) (332)
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B (2002) (317)
Hepatitis B virus genotypes in the United States: results of a nationwide study. (2003) (316)
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? (2002) (316)
Multicenter study of lamivudine therapy for hepatitis B after liver transplantation (1999) (289)
Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. (2002) (283)
Association of diabetes mellitus and chronic hepatitis C virus infection (1999) (259)
Prevalence of HBV precore/core promoter variants in the United States (2003) (225)
Benefits and risks of interferon therapy for hepatitis B (2009) (222)
Quantitative detection of hepatitis C virus RNA with a solid‐phase signal amplification method: Definition of optimal conditions for specimen collection and clinical application in interferon‐treated patients (1994) (218)
Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen (1998) (216)
Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. (1995) (214)
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg? (2015) (207)
Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. (1995) (185)
Hepatitis B: reflections on the current approach to antiviral therapy. (2008) (175)
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. (2008) (173)
Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. (1994) (172)
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. (1990) (170)
Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. (1988) (168)
Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection (1993) (162)
The role of liver biopsy in hepatitis C (1997) (159)
Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. (1992) (139)
Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial (1996) (130)
Quantitation of HBV DNA in human serum using a branched DNA (bDNA) signal amplification assay. (1995) (126)
Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. (1992) (124)
Spontaneous clearance and reactivation of hepatitis B virus infection among male homosexuals with chronic type B hepatitis. (1984) (122)
Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. (2003) (119)
Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. (1986) (119)
Morbidity of Chronic Hepatitis C as Seen in a Tertiary Care Medical Center (2004) (102)
Hepatitis B virus DNA in peripheral‐blood mononuclear cells in chronic hepatitis B after HBsAg clearance (1992) (95)
A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis (2003) (88)
Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? (2001) (87)
Comparative efficacy of adenine arabinoside 5' monophosphate and prednisone withdrawal followed by adenine arabinoside 5' monophosphate in the treatment of chronic active hepatitis type B. (1985) (86)
Quantitation of hepatitis B viral DNA by solution hybridization: Comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy (1989) (81)
Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable (2012) (80)
Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. (1990) (80)
Current treatment of chronic hepatitis B: benefits and limitations. (2005) (77)
Treatment of chronic hepatitis C with recombinant α-interferon. A multicentre randomized, controlled trial (1990) (76)
Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype. (2015) (75)
Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment (2001) (73)
Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. (1991) (72)
Hepatitis B e Antigen, DNA Polymerase Activity, and Infection of Household Contacts with Hepatitis B Virus (1979) (72)
Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen–positive liver donation: A survey of North American, European, and Asian‐Pacific transplant programs (2009) (70)
Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. (1993) (67)
Treatment of chronic hepatitis B with interferon: experience in western countries. (1989) (67)
Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature (2002) (65)
Hepatitis C RNA in liver of chronic hepatitis C patients before and after interferon alfa treatment. (1993) (63)
Preventing hepatitis B reactivation due to immunosuppressive drug treatments. (2015) (62)
Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. (1998) (61)
Therapy of hepatitis B — Viral suppression or eradication? (2006) (61)
A research agenda for curing chronic hepatitis B virus infection (2018) (61)
A Pilot Study of Extended Duration Peginterferon Alfa-2a for Patients With Hepatitis B e Antigen-Negative Chronic Hepatitis B (2007) (58)
Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment. (1995) (58)
Comparison of quality of life, work productivity and medical resource utilization of peginterferon alpha 2a vs the combination of interferon alpha 2b plus ribavirin as initial treatment in patients with chronic hepatitis C (2004) (56)
Hepatitis B Virus Replication in Damaged Endothelial Tissues of Patients with Extrahepatic Disease (2005) (55)
Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses. (1983) (54)
Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B (2013) (51)
The Lamivudine North American Transplant Group. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B (2001) (49)
Factors influencing response to interferon in chronic hepatitis B: Implications for Asian and western populations (1990) (49)
Relationship between histology, aminotransferase levels, and viral replication in chronic hepatitis B. (1990) (46)
Determination of hepatitis B phenotype using biochemical and serological markers (2017) (46)
Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy. (2016) (46)
Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases (2015) (45)
Immunosuppression in Patients with Chronic Hepatitis B (2014) (45)
Clinical predictors of response to recombinant interferon‐α treatment in patients with chronic non‐A, non‐B hepatitis (hepatitis C) (1994) (44)
Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. (2012) (44)
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy (2005) (42)
Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C (2000) (41)
Hepatitis B and liver transplantation. Problems and promises. (1993) (39)
Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results (2001) (39)
Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non‐A, non‐B fulminant hepatic failure (1996) (38)
Colonic tuberculosis diagnosed by colonoscopic biopsy. (1979) (37)
Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma (2007) (36)
Chronic hepatitis B: a critical appraisal of current approaches to therapy. (2006) (34)
Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens (2007) (32)
Acute non-A, non-B hepatitis with serum sickness-like syndrome and aplastic anemia. (1981) (32)
Immunoregulatory T Cell Subsets in Chronic Hepatitis B Virus Infection: The Influence of Homosexuality (2007) (31)
The clinical course and chronic sequelae of hepatitis B virus infection. (1981) (31)
Treatment of chronic hepatitis C with recombinant alpha-interferon. A multicentre randomized, controlled trial. The Hepatitis Interventional Therapy Group. (1990) (30)
Overview of treatment of hepatitis B: key approaches and clinical challenges. (2004) (30)
Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis be-antigen (HBeAg) seroconversion* (1998) (30)
The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. (1999) (28)
Antiviral therapy of chronic hepatitis B: past, present, and future. (1993) (26)
Interferon in the management of chronic hepatitis B (1993) (25)
Allograft transmission of hepatitis C virus infection from infected donors in cardiac transplantation (2003) (25)
Hepatitis B surface antigen quantification as a current‐day paradox: Obtaining the gold in the face of diminishing returns (2009) (24)
Hepatitis B and renal transplantation: Securing the sword of Damocles (2002) (24)
Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. (2019) (24)
Interferon therapy for chronic type B hepatitis: the promise comes of age. (1989) (23)
Comparison of quantitative HCV RNA assays in chronic hepatitis C. (1997) (23)
Entecavir and Peginterferon Alfa‐2a in Adults With Hepatitis B e Antigen–Positive Immune‐Tolerant Chronic Hepatitis B Virus Infection (2018) (23)
Hepatitis B e antigen, DNA polymerase activity, and infection of household contacts with hepatitis B virus. (1979) (23)
Hepatitis B virus replication x time equals trouble. (2006) (23)
Research priorities for the discovery of a cure for chronic hepatitis B: Report of a workshop (2017) (23)
Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy. (1996) (22)
Prevaccination screening of medical and dental students. Should low levels of antibody to hepatitis B surface antigen preclude vaccination? (1983) (21)
The management of chronic hepatitis B. (1994) (21)
Different operating conditions affect risk of hepatitis B virus infection at two residential institutions for the mentally disabled. (1986) (21)
Hepatitis B: transmission and natural history. (1993) (20)
Survey of hepatitis B viral markers at a public day school and a residential institution sharing mentally handicapped students. (1984) (20)
Hepatitis B and D (2010) (20)
Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group. (1994) (20)
How will we use the new antiviral agents for hepatitis B? (2002) (19)
Interferon-prednisone therapy for hepatitis B (1990) (19)
Effect of pancreatic proteases on intestinal lactase activity. (1980) (19)
Impact of the hepatitis B virus genotype on pre– and post–liver transplantation outcomes (2008) (17)
Aberrant pancreas and leiomyoma of the stomach: indistinguishable radiologic and endoscopic features. (1977) (17)
Chronic Hepatitis B in Pregnancy A Workshop Consensus Statement on Screening, Evaluation, and Management, Part 1 (2012) (17)
Chronic hepatitis B infection: a workshop consensus statement and algorithm. (2011) (17)
Immune globulin and hepatitis B immune globulin. Prophylactic measures for intimate contacts exposed to acute type B hepatitis. (1984) (16)
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy (2020) (16)
Efficacy, safety, and tolerability in patients switched to PEG (40 kDa) IFN α-2a (PEGASYS®) after discontinuation from interferon alfa-2b plus ribavirin (REBETRON™) combination therapy for chronic hepatitis C (2001) (15)
Chronic hepatitis B: problem patients (including patients with decompensated disease). (1995) (14)
Management of the patient with hepatitis B virus-related cirrhosis. (2003) (14)
Sustained antiviral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection (2002) (14)
Xenon-133 retention in hepatic steatosis-correlation with liver biopsy in 45 patients: concise communication. (1979) (13)
The relationship of hepatitis B e antigen, DNA polymerase activity, and titer of hepatitis B surface antigen with ongoing liver injury in chronic hepatitis B virus infection. (1982) (13)
Prevalence of hepatitis B antibodies in personnel at a children's hospital. (1985) (12)
Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance (2011) (12)
Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. (2019) (12)
INTERFERON THERAPY OF HEPATITIS B (1999) (12)
Response to hepatitis B virus vaccine in subjects with low levels of antibody to hepatitis B surface antigen. (1984) (11)
The use of HBsAg–positive organ donors: Far more than meets the eye? (2005) (11)
Clinical and immunologic features of chronic dialysis patients who fail to respond to hepatitis B vaccine. (1985) (11)
Management of chronic hepatitis B virus infection: Current perspectives for the nurse practitioner (2006) (10)
Internist diagnosis and management of chronic hepatitis B virus infection. (2012) (10)
Alcoholic liver disease presenting with marked elevation of serum alkaline phosphatase (1978) (10)
Serum HBV DNA suppression and seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B patients. (2001) (10)
Rosette Inhibitory Factor: T‐Lymphocyte Subpopulation Specificity and Potential Immunoregulatory Role in Hepatitis B Virus Infection (2007) (10)
Hepatitis B virus reactivation during direct‐acting antiviral treatment of chronic hepatitis C: A hidden danger of an otherwise major success story (2017) (10)
Screening of health care workers before hepatitis B vaccination: more questions than answers. (1985) (9)
HLA class I antigen expression as a measure of response to antiviral therapy of chronic hepatitis B (1991) (9)
The use of corticosteroids in conjunction with antiviral therapy in chronic hepatitis B with ongoing viral replication. (1986) (9)
Post-transfusion hepatitis leading to chronic hepatitis. (1978) (9)
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B (2010) (9)
Halting the natural history of hepatitis B viral infection: a paradigm shift. (2007) (9)
Quantitative temporal analysis of 99mTechnetium p-isopropyl-iminodiacetic acid (PIPIDA) as a measure of hepatic function in health and disease. (1981) (9)
Corticosteroid therapy for chronic active hepatitis B: Is a little too much? (1986) (8)
Customizing the management of chronic hepatitis B virus infection. (2007) (8)
Tumor necrosis factor inhibitor therapy for hepatitis B virus–infected individuals: How loud is the alarm bell? (2015) (7)
Posttransplantation: emerging and future therapies. (2000) (7)
Hepatitis B reactivation from immunosuppressive drug therapy: A global menace (2015) (7)
Editorial: Measurement of HBsAg Concentration During Antiviral Therapy of Hepatitis B: Who, When, and Why (2011) (7)
Patient Management and Clinical Decision Making in HBV – Aims of Therapy and What we can Achieve (2010) (6)
Pilot study of intron-A and ribavirin vs intron-A and amantadine in interferon non-responders with chronic hepatitis C (1998) (6)
Filtration and immunoprecipitation in the elimination of DNA polymerase activity associated with bacterial contamination of sera positive for hepatitis B e antigen and its corresponding antibody. (1978) (6)
Short‐Term Corticosteroid Therapy in Combination With Lamivudine: A Case of Déjà Vu? (2000) (6)
Amantidine monotherapy in patients with chronic hepatitis C (1998) (5)
Discordant e antigen, DNA polymerase activity, and Dane particle responses in two patients representing an index case-contact case pair with hepatitis B virus infection. (1977) (5)
The A to Z of new hepatotropic agents: human hepatitis viruses and monkey business. (1996) (5)
Incidence and prediction of HBsAg seroclearance in a prospective multi‐ethnic HBeAg‐negative chronic hepatitis B cohort (2021) (5)
Case studies of the hepatitis B patient: a panel discussion. (2000) (5)
Screening for Hepatitis B in the Immigrant Population and Individuals Who are in Need of Immunosuppressive Drug Therapy (2015) (5)
Immunopathogenesis of Chronic Hepatitis B and the Clinical Events That Shape its Natural History (2014) (4)
A problem with a severed feeding tube. (1983) (4)
Interferon for hepatitis B: US experience. (1993) (4)
Antiviral therapy to prevent and treat hepatitis B virus infection in hepatic allografts. (2000) (4)
Antiviral theraphy of chronic viral hepatitis (1988) (4)
Oral cholecystography in chronic renal insufficiency (CRI) (1978) (4)
IS LAMIVUDINE BENEFICIAL IN HBSAG+ PATIENTS AWAITING LIVER TRANSPLANTATION? EXPERIENCE IN 182 NORTH AMERICAN PATIENTS. (1999) (4)
Complementary use of computerized tomography and technetium scanning in the diagnosis of accessory spleen (1980) (4)
A partial characterization of hepatitis B e antigen. (1979) (4)
535 SAFETY AND EFFICACY OF ENTECAVIR IN PATIENTS RECEIVING LIVER TRANSPLANT DUE TO CHRONIC HEPATITIS B (2012) (4)
Therapy with PEGASYS® demonstrates similar efficacy and significantly improved tolerability, quality of life and work productivity compared with REBETRON™ in patients with chronic hepatitis C (2001) (4)
Withholding Statins in Patients with Underlying Liver Disease: Wise or Unwise? (2010) (4)
Hepatitis B virus treatment: Which patients require immediate treatment (2013) (4)
Prevalence of HBV precore and core promotor variants in the United States — results of a nation-wide study (2002) (3)
Changes in serum hepatitis B surface and e antigen, interferon‐inducible protein 10, and aminotransferase levels during combination therapy of immune‐tolerant chronic hepatitis B (2022) (3)
Interferon in clinically stable, replicative chronic hepatitis B: Good news for some (1991) (3)
Suppression of T helper function: An immunoregulatory effect of rosette inhibitory factor in hepatitis B virus infection (1985) (3)
438 Continued safety and efficacy of adding adefovir dipivoxil (ADV) to ongoing lamivudine (LAM) therapy in compensated chronic hepatitis B (CHB) patients with YMDD variant HBV: 2 year results (2004) (2)
Characteristics of older patients with immunotolerant chronic hepatitis B virus infection. (2022) (2)
Article Commentary: Reactivated Hepatitis B Due to Medical Interventions: The Clinical Spectrum Expands (2011) (2)
Reactivation of Hepatitis B Virus Due to Cancer Chemotherapy and Other Immunosuppressive Drug Therapy (2016) (2)
Treatment of posttransplantation hepatitis B. (1997) (2)
Antiviral agents in the treatment of chronic viral hepatitis. (1992) (2)
Book Review Viral Hepatitis: Practical evaluation and treatment By Teddy F. Bader. 248 pp. Seattle, Hogrefe and Huber, 1995. $49. 0-88937-133-4 (1995) (1)
Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN α-2a (PEGASYS®) or standard interferon Alfa-2b/ribavirin (REBETRON™) combination therapy (2001) (1)
Chapter 31 – Hepatitis B (2006) (1)
Effect of newer oral antiviral agents on future therapy of chronic hepatitis B (2010) (1)
e Antigen, DNA polymerase activity, and infection of house-hold contacts with hepatitis B virus (1978) (1)
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. (2019) (1)
Long term hepatitis B therapy with lamivudine: a major step forward but can we do even better? (2005) (1)
Gastric pseudolymphoma. A spectrum of presenting features and diagnostic considerations. (1976) (1)
Entering the new era of therapy for HBV and HCV infections. (2010) (1)
Should spouses of hepatitis B surface antigen carriers receive hepatitis vaccine? (1983) (1)
O116 HEPATITIS B SURFACE ANTIGEN (HBsAg) LEVELS DIFFER ACROSS HBV GENOTYPE AND PHENOTYPE: RESULTS FROM THE ADULT COHORT STUDY OF THE NIDDK-SPONSORED HEPATITIS B RESEARCH NETWORK (2014) (1)
Hepatitis B: Treatment strategies for currently available drugs (2003) (1)
Economic analysis of early serum hepatitis C virus RNA testing in patients with chronic hepatitis C on interferon therapy. (2000) (1)
Uncommon Forms of Viral Hepatitis (1989) (1)
Viral suppression and HBeAg-seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B infection. (2001) (1)
An evaluation demonstrating continued efficacy and improved safety and tolerability in 17 patients switched to PEGASYS® after discontinuation from REBETRON™ for the treatment of chronic hepatitis C (2001) (1)
PID11 PEGYLATED (40KDA) INTERFERON ALFA-2A (PEGASYS®) SIGNIFICANTLY IMPROVES TOLERABILITY, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C (2001) (1)
P644 PREDICTION OF ALT FLARES IN THE NATURAL HISTORY OF CHRONIC HEPATITIS B INFECTION: A PROSPECTIVE COHORT STUDY FROM THE NIDDK HEPATITIS B RESEARCH NETWORK (HBRN) (2014) (0)
Clinicopathology Conferences Hepatitis and Cholestasis in a Middle-Aged Woman (1998) (0)
Frequency and outcome of de novo hepatitis C infection in heart transplant recipients Relationship to donor genotype, donor HCV RNA level, and immunosuppression post-transplant (2001) (0)
M1914 HBV Prevention Strategies Using anti-HBc Positive Liver Donors (2008) (0)
An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus (2022) (0)
Herbal hepatitis due to use of alternative medicines for Lyme disease (2021) (0)
Hepatitis B: Sexual Contacts-Reply (1985) (0)
Oral cholecystography in chronic renal insufficiency (1978) (0)
Viral hepatitis management. Standards for the future. Case studies. (1993) (0)
Treatment of antiviral therapy for chronic hepatitis B: A disease in evolution (2005) (0)
Withdrawal of long-term nucleotide analogue therapy in chronic hepatitis B: Outcomes from the withdrawal phase of the HBRN immune active treatment trial. (2023) (0)
Carman, W F see Jazayeri, M. Carnot, F see Lebray, P. Caronia, S, McGarvey, M J, Goldin, R D &. Foster, G R. Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas ... (2004) (0)
Therapy for hepatitis B virus infection. (1994) (0)
Does past infection with hepatitis B increase the risk of hepatocellular carcinoma in hepatitis C induced cirrhosis (2003) (0)
Computerized tomography (CT), abdominal ultrasound (US), and Tc-99m pipida (PIP) imaging in intrahepatic and extrahepatic cholestasis (1980) (0)
HBeAG concentration can be used to predict response and monitor the effects of treatment in chronic hepatitis B: A comparison to HBV DNA testing (1993) (0)
Overview of Hepatitis B Virus Reactivation. (2021) (0)
Temporal analysis of hepatobiliary transit of Tc-99m pipida (PIP): Application to normal volunteers and cholestatic subjects (1980) (0)
The role of additives in allergic vasculitis during intravenous hyperalimentation (1975) (0)
Chronic hepatitis B responds to interferon alfa-2b, study shows (1991) (0)
Rosette inhibitory factor (RIF) augments cyclic AMP generation by helper T lymphocytes. (1986) (0)
The management of chronic hepatitis B. Discussion (1994) (0)
Antiviral therapy for chronic viral hepatitis (1991) (0)
IgM anti-HCV testing in chronic hepatitis C: Correlation with response to IFN, level of virus, and disease activity (1995) (0)
Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B. (2023) (0)
Case Study in the Management of Patients with HBV-Related Decompensated Cirrhosis (2004) (0)
Hepatic extraction of Tc-99m sulfur colloid (TSC) and hepatic transport of Tc-99m pipida (PIP) in normal subjects and acute viral hepatitis (1980) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert P. Perrillo?

Robert P. Perrillo is affiliated with the following schools:

Baylor University